• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

European Council Advances SPC Waiver For Generics; Negotiations Coming

16/01/2019 by David Branigan, Intellectual Property Watch Leave a Comment

The European Union Council of member states has approved a mandate for negotiations with the EU Parliament concerning a draft regulation aimed at boosting EU-based generic and biosimilar manufacturing for export by providing an exception to the extended intellectual property protection granted by special protection certificates (SPCs). The mandate brings the draft regulation a step closer to adoption, and it also suggests that Parliament’s recent amendments to the regulation are likely be key areas of debate in the negotiations, which are expected to begin in the coming weeks.

Filed Under: IP Policies, Language, Subscribers, Themes, Venues, Biodiversity/Genetic Resources/Biotech, English, Europe, Health & IP, Innovation/ R&D, New Technologies, Patents/Designs/Trade Secrets, Regional Policy

UNCTAD Finds Growth In Global Creative Economy Led By ‘New Breed’ Of Countries

15/01/2019 by David Branigan, Intellectual Property Watch Leave a Comment

In a new report on the creative economy, the United Nations Conference on Trade and Development (UNCTAD) found that despite a slowdown in global trade since the 2008 financial crisis, the creative economy has remained robust and has exhibited significant growth. Leading this growth is China, with four times the creative goods exports as the United States in 2015.

Filed Under: IP Policies, Language, Subscribers, Themes, Venues, Asia/Pacific, Copyright Policy, Development, English, Information and Communications Technology/ Broadcasting, New Technologies, Regional Policy, United Nations - other

India Proposes Expediting Patents For Women, Small Entities, Waiving PCT Fees

20/12/2018 by Intellectual Property Watch Leave a Comment

The Indian Ministry of Commerce and Industry from the Department of Industrial Policy and Promotion recently published draft amendments to the Patent Rules of 2003 that would expand the eligibility for expedited examination of patent applications to include women and small entities, and would waive the fees for online filing of international patent applications through the Patent Cooperation Treaty (PCT), among other changes.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Asia/Pacific, Development, English, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy, WIPO

WHO Report Shows Global Progress On Influenza Preparedness Response

18/12/2018 by David Branigan, Intellectual Property Watch Leave a Comment

The World Health Organization has released a new report showing that significant progress has been made to build national and global preparedness for future influenza pandemics. This progress resulted from the collaborative multi-sectoral implementation of a WHO plan, funded by the benefit-sharing contributions of industry partners, to strengthen global health security against pandemic influenza.

Filed Under: IP Policies, Language, Themes, Venues, Biodiversity/Genetic Resources/Biotech, English, Finance, Health & IP, Human Rights, Patents/Designs/Trade Secrets, WHO

WHO To Form Expert Panel On Challenges Of Human Gene Editing

17/12/2018 by Intellectual Property Watch 1 Comment

The World Health Organization has announced it will be establishing a global multidisciplinary panel of experts “to examine the scientific, ethical, social and legal challenges associated with human gene editing.”

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Health & IP, Human Rights, New Technologies, Patents/Designs/Trade Secrets, WHO

EU Committees Amend SPC Manufacturing Waiver, Push Access To Generics, Biosimilars

14/12/2018 by David Branigan, Intellectual Property Watch Leave a Comment

The European Parliamentary Committees on Health and Trade have each voted in recent weeks to adopt amendments to the proposed Special Protection Certificate (SPC) manufacturing waiver, an intellectual property exception for the EU generic and biosimilar industry. The amendments include provisions that push the waiver toward increasing EU generic and biosimilar industry competitiveness in EU markets, and improving access for EU patients to affordable medicines. The waiver and amendments still have several hurdles to go, including a vote by the Legal Affairs Committee planned for January.

Filed Under: IP Policies, Language, Subscribers, Themes, Venues, English, Europe, Finance, Health & IP, Patents/Designs/Trade Secrets, Regional Policy

Experts Call For Global Accountability Mechanism For Access To Essential Medicines

10/12/2018 by Intellectual Property Watch 1 Comment

Global health experts, including senior officials at the World Health Organization, are calling for a global accountability mechanism for access to essential medicines, noting that a the lack of data on medicines affordability and national pharmaceutical expenditures has hindered this process, according a recent article published in UK medical journal The Lancet.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Europe, Health & IP, New Technologies, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer, WHO

OECD Report Presents Policies To Balance Innovation With Access To Medicines

05/12/2018 by Intellectual Property Watch Leave a Comment

The Organisation for Economic Cooperation and Development (OECD) has released a new report that presents policy options for countries to strike a better balance between promoting financial incentives for pharmaceutical innovation and ensuring affordable access to medicines. Finding this balance, the report explains, will be essential for ensuring the sustainability of health systems.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Finance, Health & IP, Innovation/ R&D, Other International Orgs, Patents/Designs/Trade Secrets

US IP Stakeholders Seek To Strengthen Public Support For IP, Ensure Future US Competitiveness

04/12/2018 by David Branigan, Intellectual Property Watch Leave a Comment

NEW YORK — United States intellectual property stakeholders from academic, business and legal backgrounds gathered recently to discuss how to increase public support to strengthen the intellectual property rights system in the US, in light of China’s steady rise in numbers of patent and trademark filings. US IP stakeholders argued that developing public awareness and understanding of IP is key to building this support, with some holding diverging views on how to go about this.

Filed Under: Features, IP Policies, Language, Subscribers, Themes, Venues, Access to Knowledge/ Education, Copyright Policy, Enforcement, English, Finance, Innovation/ R&D, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy, Trademarks/Geographical Indications/Domains

Study Finds Arthritis Drug Enbrel Overpatented, Overpriced in US

04/12/2018 by Intellectual Property Watch Leave a Comment

Initiative for Medicines, Access & Knowledge (I-MAK) released a new study yesterday showing that the rheumatoid arthritis drug Enbrel has been overpatented by drugmaker Amgen, which has filed a total of 57 patents on the drug in the United States. Together, these patents were said to delay market competition by 39 years, rather than the standard 20 years for one patent. The study found that this market exclusivity for Enbrel resulted in US$ 8 billion dollars in sales in 2017 alone.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Finance, Health & IP, Human Rights, Innovation/ R&D, North America, Patents/Designs/Trade Secrets, Regional Policy

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2021 · Global Policy Reporting